Gilead Sciences to acquire oral IL-23R inhibitor HCXT-2001 from PepStar
The program is investigational, and seller PepStar Therapeutics Limited is a privately held, clinical-stage biotechnology company.
GetSignal Gilead Sciences, Inc. GILD
Gilead Sciences said on October 22, 2026, that it has entered into a definitive agreement to acquire an oral IL-23R inhibitor program from PepStar Therapeutics Limited.
The program includes its lead asset, HCXT-2001, and Gilead Sciences said it adds to the company's inflammation pipeline in IBD.
Key facts
- Seller
- PepStar Therapeutics Limited
- Lead asset
- HCXT-2001
- Deal status
- Definitive agreement entered into
Source: The company's release on Business Wire, October 22, 2026.
Written by GetSignal with AI from the company's press release.
Not investment advice.
